Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs WD 40 Company (WDFC) Price & Performance

Eli Lilly And CoTrade
WD 40 CompanyTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs WD 40 Company — how do they compare? Eli Lilly And Co trades at $1,225.38 (market cap $1.08T), while WD 40 Company trades at $233.26 (market cap $3.13B). The key difference: Eli Lilly And Co is far larger — about 345× WD 40 Company's market cap, and WD 40 Company pays the higher dividend (1.75%). Which is the better fit depends on your goals.

LLYWDFC
Market Cap
$1.08T$3.13B
Sector
HealthTechnology
52-Week High
$1.24K$264.91
52-Week Low
$639.43$187.52
Enterprise Value
$1.13T$3.18B
Dividend Yield
0.57%1.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

WD 40 Company

WD-40 Company (WDFC) trades at $232.9, down 0.69% today, with strong technical momentum showing bullish moving averages and key support at $230. The company reported impressive Q2 2026 earnings of $2.33 per share, beating estimates by 49%, while revenue growth continues with 2026 projections at $675 million. Recent news highlights institutional buying and positive analyst coverage, though valuation metrics remain elevated with a P/E of 35.39.

WDFC demonstrates solid fundamentals with consistent profitability (13.22% net margin) and strong brand positioning, but faces margin pressure from rising input costs. Analyst sentiment is mixed with 71% hold ratings, suggesting cautious optimism. Key risks include valuation concerns and cost inflation, while the company's dividend policy and global brand recognition provide stability for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About WD 40 Company

WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.

Read more on WDFC